Restricted accessReview articleFirst published online 2024-8
The association of the prothrombin A19911G single-nucleotide polymorphism and the risk of venous thromboembolism: A systematic review and meta-analysis
The study employed meta-analysis to provide a comprehensive synthesis of evidence regarding the association between the prothrombin A19911G polymorphism and the risk of venous thromboembolism (VTE).
Method
The databases were searched to identify studies investigating the association between the prothrombin A19911G polymorphism and the risk of VTE. Meta-analysis was conducted using Stata 14.0 software.
Results
A total of five literature studies were included, involving 14,001 participants. Meta-analysis demonstrated that prothrombin A19911G polymorphism increased the risk of VTE (G vs A: OR = 1.17, 95% CI = 1.11–1.22, p < .00001; GG + AG vs AA: OR = 1.22, 95% CI = 1.13–1.31, p < .00001; GG vs AG + AA: OR = 1.23, 95% CI = 1.14–1.33, p < .00001; AG vs AA: OR = 1.15, 95% CI = 1.06–1.25, p = .0006; GG vs AA: OR = 1.34, 95% CI = 1.22–1.48, p < .00001).
Conclusion
The polymorphism of prothrombin A19911G enhances the susceptibility to VTE.
KeyNSKhoranaAAKudererNM, et al.Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol2020; 38(5): 496–520.
3.
BartholomewJR. Update on the management of venous thromboembolism. Cleve Clin J Med2017; 84(12 Suppl 3): 39–46.
4.
PoliDGrifoniEAntonucciE, et al.Incidence of recurrent venous thromboembolism and of chronic thromboembolic pulmonary hypertension in patients after a first episode of pulmonary embolism. J Thromb Thrombolysis2010; 30(3): 294–299.
5.
LutseyPLEvensenLHThenappanT, et al.Incidence and risk factors of pulmonary hypertension after venous thromboembolism: an analysis of a large health care database. J Am Heart Assoc2022; 11(14): e024358.
6.
LecumberriRAlfonsoAJiménezDRIETE investigators, et al.Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism. Thromb Haemostasis2013; 110(4): 834–843.
7.
KonstantinidesSVMeyerGBecattiniCESC Scientific Document Group, et al.2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS). Eur Heart J2020; 41(4): 543–603.
8.
KhanFTritschlerTKahnSR, et al.Venous thromboembolism. Lancet2021; 398(10294): 64–77.
9.
OrtelTLNeumannIAgenoW, et al.American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv2020; 4(19): 4693–4738.
10.
LutseyPLZakaiNA. Epidemiology and prevention of venous thromboembolism. Nat Rev Cardiol2023; 20(4): 248–262.
11.
FargeDFrereCConnorsJMInternational Initiative on Thrombosis and Cancer ITAC Advisory Panel, et al.2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol2022; 23(7): e334–e347.
12.
KujovichJL. Factor V leiden thrombophilia. Genet Med2011; 13(1): 1–16.
13.
JadaonMM. Epidemiology of prothrombin G20210A mutation in the mediterranean region. Mediterr J Hematol Infect Dis2011; 3(1): e2011054.
14.
HotoleanuC. Genetic risk factors in venous thromboembolism. Adv Exp Med Biol2017; 906: 253–272.
15.
ZhangYZhangZShuS, et al.The genetics of venous thromboembolism: a systematic review of thrombophilia families. J Thromb Thrombolysis2021; 51(2): 359–369.
16.
ThibordFKlarinDBrodyJA, et al.Cross-ancestry investigation of venous thromboembolism genomic predictors. Circulation2022; 146(16): 1225–1242.
17.
TangLHuY. Ethnic diversity in the genetics of venous thromboembolism. Thromb Haemostasis2015; 114(5): 901–909.
18.
SeyerleAALaurieCACoombesBJ, et al.Whole genome analysis of venous thromboembolism: the trans-omics for precision medicine program. Circ Genom Precis Med2023; 16(2): e003532.
19.
WahbaMAIsmailMASaadAA, et al.Impact of thrombophilic genes mutations on thrombosis risk in Egyptian nonmetastatic cancer patients. Blood Coagul Fibrinolysis2015; 26(3): 309–315.
20.
PrunerIFarmMTomicB, et al.The silence speaks, but we do not listen: synonymous c.1824C > T gene variant in the last exon of the prothrombin gene as a new prothrombotic risk factor. Clin Chem2020; 66(2): 379–389.
21.
GirolamiACosiEFerrariS, et al.Prothrombin: another clotting factor after FV that is involved both in bleeding and thrombosis. Clin Appl Thromb Hemost2018; 24(6): 845–849.
22.
PantAKopecAKLuyendykJP. Role of the blood coagulation cascade in hepatic fibrosis. Am J Physiol Gastrointest Liver Physiol2018; 315(2): G171–G176.
23.
LiHHuangYWuX, et al.Effects of hemocoagulase agkistrodon on the coagulation factors and its procoagulant activities. Drug Des Dev Ther2018; 12: 1385–1398.
24.
LarsenJBHvasAM. Thrombin: a pivotal player in hemostasis and beyond. Semin Thromb Hemost2021; 47(7): 759–774.
25.
LeeSLeeCHSeoMS, et al.Integrative analyses of genes about venous thromboembolism: an umbrella review of systematic reviews and meta-analyses. Medicine2022; 101(43): e31162.
26.
AshorobiDAmeerMAFernandezR. Thrombosis. St. Petersburg, FL: StatPearls, 2023.
27.
PoortSRRosendaalFRReitsmaPH, et al.A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood1996; 88(10): 3698–3703.
28.
AttiaFMMikhailidisDPReffatSA. Prothrombin gene G20210A mutation in acute deep venous thrombosis patients with poor response to warfarin therapy. Open Cardiovasc Med J2009; 3: 147–151.
29.
RingwaldJBergerAAdlerW, et al.Genetic polymorphisms in venous thrombosis and pulmonary embolism after total hip arthroplasty: a pilot study. Clin Orthop Relat Res2009; 467(6): 1507–1515.
30.
DjordjevicVPrunerITomicB, et al.The 3′ end prothrombin gene variants in patients with different thrombotic events. Lab Med2014; 45(4): 309–314.
31.
BarcellonaDFenuLCauliC, et al.Allele 4G of gene PAI-1 associated with prothrombin mutation G20210A increases the risk for venous thrombosis. Thromb Haemostasis2003; 90(6): 1061–1064.
32.
StangA. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol2010; 25(9): 603–605.
33.
Pérez-CeballosECorralJAlbercaI, et al.Prothrombin A19911G and G20210A polymorphisms’ role in thrombosis. Br J Haematol2002; 118(2): 610–614.
34.
MartinelliIBucciarelliPDe StefanoV, et al.Effect of prothrombin 19911 A > G polymorphism on the risk of cerebral sinus-venous thrombosis. Eur J Neurol2010; 17(12): 1482–1485.
35.
MartinelliIBattaglioliTTosettoA, et al.Prothrombin A19911G polymorphism and the risk of venous thromboembolism. J Thromb Haemostasis2006; 4(12): 2582–2586.
36.
LimpergerVKenetGKiesauB, et al.Role of prothrombin 19911 A > G polymorphism, blood group and male gender in patients with venous thromboembolism: results of a German cohort study. J Thromb Thrombolysis2021; 51(2): 494–501.
37.
ChinthammitrYVosHLRosendaalFR, et al.The association of prothrombin A19911G polymorphism with plasma prothrombin activity and venous thrombosis: results of the MEGA study, a large population-based case-control study. J Thromb Haemostasis2006; 4(12): 2587–2592.
38.
RosendaalFR. Venous thrombosis: a multicausal disease. Lancet1999; 353(9159): 1167–1173.
39.
SpethJ. Guidelines in practice: prevention of venous thromboembolism. AORN J2023; 118(5): 321–328.
40.
SimoneBDe StefanoVLeonciniE, et al.Risk of venous thromboembolism associated with single and combined effects of factor V leiden, prothrombin 20210A and methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. Eur J Epidemiol2013; 28(8): 621–647.
41.
von AhsenNOellerichM. The intronic prothrombin 19911A > G polymorphism influences splicing efficiency and modulates effects of the 20210G > A polymorphism on mRNA amount and expression in a stable reporter gene assay system. Blood2004; 103(2): 586–593.
42.
EmmerichJRosendaalFRCattaneoM, et al.Combined effect of factor V leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study group for pooled-analysis in venous thromboembolism. Thromb Haemostasis2001; 86(3): 809–816.
43.
AradjanskiMDjordjevicVPrunerI, et al.The 3′ end prothrombin gene variants in Serbian patients with idiopathic thrombophilia. Balkan J Med Genet2014; 17(2): 43–48.
44.
DemirciFYDressenASKammererCM, et al.Functional polymorphisms of the coagulation factor II gene (F2) and susceptibility to systemic lupus erythematosus. J Rheumatol2011; 38(4): 652–657.
45.
PastoriDCormaciVMMarucciS, et al.A comprehensive review of risk factors for venous thromboembolism: from epidemiology to pathophysiology. Int J Mol Sci2023; 24(4): 3169.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
